JPWO2022260064A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022260064A5
JPWO2022260064A5 JP2023527886A JP2023527886A JPWO2022260064A5 JP WO2022260064 A5 JPWO2022260064 A5 JP WO2022260064A5 JP 2023527886 A JP2023527886 A JP 2023527886A JP 2023527886 A JP2023527886 A JP 2023527886A JP WO2022260064 A5 JPWO2022260064 A5 JP WO2022260064A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
formula
salt
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527886A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022260064A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/023076 external-priority patent/WO2022260064A1/ja
Publication of JPWO2022260064A1 publication Critical patent/JPWO2022260064A1/ja
Publication of JPWO2022260064A5 publication Critical patent/JPWO2022260064A5/ja
Pending legal-status Critical Current

Links

JP2023527886A 2021-06-08 2022-06-08 Pending JPWO2022260064A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021096206 2021-06-08
PCT/JP2022/023076 WO2022260064A1 (ja) 2021-06-08 2022-06-08 ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤

Publications (2)

Publication Number Publication Date
JPWO2022260064A1 JPWO2022260064A1 (cg-RX-API-DMAC7.html) 2022-12-15
JPWO2022260064A5 true JPWO2022260064A5 (cg-RX-API-DMAC7.html) 2025-06-17

Family

ID=84426023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527886A Pending JPWO2022260064A1 (cg-RX-API-DMAC7.html) 2021-06-08 2022-06-08

Country Status (12)

Country Link
US (1) US20240293402A1 (cg-RX-API-DMAC7.html)
EP (1) EP4353233A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022260064A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240018523A (cg-RX-API-DMAC7.html)
CN (1) CN117460511A (cg-RX-API-DMAC7.html)
AU (1) AU2022288895A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023708A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221186A1 (cg-RX-API-DMAC7.html)
IL (1) IL309056A (cg-RX-API-DMAC7.html)
MX (1) MX2023014507A (cg-RX-API-DMAC7.html)
TW (1) TW202317118A (cg-RX-API-DMAC7.html)
WO (1) WO2022260064A1 (cg-RX-API-DMAC7.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012012421A (es) 2010-04-28 2012-12-17 Astellas Pharma Inc Compuestos tetrahidrobenzotiofena.
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PL2772490T3 (pl) 2011-10-27 2016-11-30 Aminoalkilo-podstawiona pochodna n-tienylobenzamidu
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
AU2014230552B2 (en) * 2013-03-13 2017-11-16 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative
US9499553B2 (en) * 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
EP4374877A3 (en) 2014-09-12 2024-07-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification.
MX376202B (es) 2016-08-15 2025-03-07 Lilly Co Eli Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
US12097204B2 (en) * 2018-09-03 2024-09-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof

Similar Documents

Publication Publication Date Title
US7728169B2 (en) Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use
JP2022542804A5 (cg-RX-API-DMAC7.html)
AU2008268537B2 (en) Tableted compositions containing atazanavir
EP2178511A2 (en) Tableted compositions containing atazanavir
AU2008268625B2 (en) Tableted compositions containing atazanavir
US9107836B2 (en) Formulation
US7060854B2 (en) Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
EP2178512A2 (en) Tableted compositions containing atazanavir
WO2019142207A1 (en) Pharmaceutical compositions comprising ibrutinib
JP2023548855A5 (cg-RX-API-DMAC7.html)
JP7226697B2 (ja) ブロナンセリン含有錠剤
WO2019244171A1 (en) Stable oral pharmaceutical composition of amorphous empagliflozin and process for preparing thereof
JP2024500545A5 (cg-RX-API-DMAC7.html)
JP4684545B2 (ja) 溶出性の良好なイソキサゾール誘導体経口製剤
US20120121722A1 (en) Atazanavir formulations
EP1776102A1 (en) Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
WO2024084496A1 (en) Pharmaceutical compositions comprising acalabrutinib maleate
EA049027B1 (ru) Двухслойная таблетка, содержащая эзетимиб и аторвастатин
AU2004251744B2 (en) The polymorphic Form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butryric acid
AU2011325235B8 (en) A composition comprising S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium
EA045648B1 (ru) Фармацевтическая композиция, включающая эзомепразол
JP2018203692A (ja) フェブキソスタット結晶の解砕工程が含まれる、錠剤の製造方法
HK1082192B (en) Composition for treating hyperlipidemia